Parisian medtech company, BrightHeart, has obtained a CE mark for its artificial intelligence (AI)-based tool to optimise the prenatal ultrasound process – marking a commercial expansion for the technology following its prior clearance in the US.

Dubbed the B-Right AI Platform, BrightHeart’s technology is designed to address the variability in the identification of heart defects during prenatal scans, with up to 50% remaining undetected before birth due to differences in workflow, expertise and operator experience between sites, the company claims.